

Good results for zone MPC-based artificial pancreas

15 June 2017



(HealthDay)—A zone model predictive control (MPC)-based artificial pancreas (AP) system improves glycemic control in a home-use environment, according to a study published online June 5 in *Diabetes Care*.

Gregory P. Forlenza, M.D., from the University of Colorado Denver, and colleagues conducted an outpatient randomized crossover trial to examine the safety and efficacy of a zone-MPC-based AP system versus sensor-augmented pump (SAP) therapy. Nineteen adults participated in the crossover study involving two weeks of use of a smartphone-based AP [system](#) and two weeks of SAP therapy.

The researchers found that AP correlated with improved percent time at 70 to 140 mg/dL (48.1 versus 39.2 percent) and time at 70 to 180 mg/dL (71.6 versus 65.2 percent) compared with SAP and with decreased percent time

APA citation: Good results for zone MPC-based artificial pancreas (2017, June 15) retrieved 28 November 2020 from <https://medicalxpress.com/news/2017-06-good-results-zone-mpc-based-artificial.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.